Buy CJC-1295 (no DAC) + Ipamorelin 10 mg in Australia
CJC-1295 (no DAC) + Ipamorelin 10 mg, typed by buyers as CJC 1295 ipamorelin, is $124.99 a vial in Australia from Australian Research Peptides, supplier to laboratories and researchers, in stock; an order paid before 12pm Sydney time on a business day goes out that day. Both peptides are freeze-dried together at a fixed ratio. The 29-amino-acid CJC-1295 half is a modified copy of growth-hormone-releasing hormone and binds the GHRH receptor; the five-amino-acid ipamorelin half binds the ghrelin receptor. Both are studied in growth hormone research, and ARP ships to every state and territory. In vitro research purposes only.
GHRH and Secretagogue Research · Lyophilised Powder · Independently lab-tested · SKU 45388
$124.99
1
Presentation
10 mg per vial
Grade
Research Grade
Form
Lyophilised Powder
Category
GHRH and Secretagogue Research
Same-day dispatch on business-day orders completed before 12pm Sydney time, Mon–Fri
Tracked shipping Australia-wide ·typically 1–2 business days to most areas by Express Post · free post over $199, free Express over $299
Batch certificates — published in the COA library
For in vitro research purposes only. Not for human consumption. Not for animal consumption. This product is not a drug, food, cosmetic, or dietary supplement. ARP gives no usage, medical or therapeutic guidance of its own.
CJC-1295 (no DAC) + Ipamorelin · 10 mg
$124.99
Browse all GHRH and Secretagogue Research
About CJC-1295 (no DAC) + Ipamorelin
This vial holds two peptides with two different receptor targets. CJC-1295 without DAC is a modified copy of the first 29 amino acids of growth-hormone-releasing hormone, the signal the hypothalamus sends down to the pituitary gland, where the receptor for it sits on the growth-hormone cells. Ipamorelin is five amino acids long and binds a separate target, the growth hormone secretagogue receptor — the one ghrelin binds. An agonist is a molecule that binds a receptor and switches it on. Both molecules are studied in growth hormone research.
Australian Research Peptides supplies the no-DAC form, and the distinction matters. CJC-1295 exists in two versions that are routinely confused. The DAC version carries an added Drug Affinity Complex, a lysine linked through maleimidopropionic acid, which binds serum albumin — a protein that circulates in the blood. That is a structural difference, and the reason the two forms are not interchangeable. The no-DAC version has no such tail, and it is the same compound catalogued elsewhere as Modified GRF (1-29). Both peptides dry together into one powder, so the strength shown covers the pair rather than either one alone.
Australian Research Peptides supplies the pair as a single freeze-dried solid, white to off-white, sealed in a tamper-evident glass vial. Nothing separates the two peptides once they are in that glass, which is why a reconstitution volume sets concentration and can never set ratio. The material is a laboratory reference compound, characterised for work in glassware and cell culture rather than for any use in a living subject.
What is in the vial
| Component | Amount per vial |
|---|---|
| CJC-1295 (no DAC) — no DAC — not the DAC-modified analogue; also catalogued as Modified GRF (1-29) | ~5 mg |
| Ipamorelin | ~5 mg |
| Total | 10 mg per vial |
CJC-1295 (no DAC) + Ipamorelin specifications, storage and shipping
- Compound: CJC-1295 (no DAC) + Ipamorelin
- Also known as: CJC-1295 without DAC (Modified GRF (1-29)) with ipamorelin
- Class: Two-peptide blend: a growth-hormone-releasing-hormone analogue with a growth-hormone secretagogue-receptor ligand
- Appearance: White to off-white lyophilised powder
- Sizes & SKUs: 10 mg (45388)
- Presentation: sealed glass vial
- Form: Lyophilised Powder
- Grade: Research grade
- Testing: Independently lab-tested for identity and amount before release — the laboratory's report for this blend gives a measured amount for each peptide and no purity figure
- Identity confirmation: Mass spectrometry
- Certificates: issued by Janoshik, an independent laboratory, and published in the COA library
- Classification: In vitro research purposes only — laboratory reference material
- Lyophilised — long term
- −20 °C to −80 °C — long-term storage
- Lyophilised — short term
- 2–8 °C — refrigerated, for a few months
- Reconstituted
- 2–8 °C — use within 8–12 weeks
CJC-1295 (no DAC) + Ipamorelin is independently lab-tested for identity and amount. The full laboratory report is published in the COA library. CJC-1295 (no DAC) + Ipamorelin is tested by Janoshik, an independent laboratory, commissioned by the manufacturer rather than by Australian Research Peptides.
- CJC-1295 (no DAC) + Ipamorelin 10 mg: measured content Ipamorelin 5.48 mg · CJC-1295 (mod GRF 1-29) 5.41 mg · CJC-1295 DAC not detected · laboratory batch 2026-06 · analysed 22 June 2026
Business-day orders before 12pm Sydney time are dispatched the same day with tracked shipping. Standard delivery within Australia typically takes 2–5 business days. See Shipping & Delivery for details, and follow your parcel on the Track Order page.
For in vitro research purposes only. Not for human consumption. Not for animal consumption. Not a drug, food, cosmetic, or dietary supplement. No therapeutic or medical claims are made.
Questions about CJC-1295 (no DAC) + Ipamorelin
This question guide from Australian Research Peptides covers CJC-1295 (no DAC) + Ipamorelin in Australia: what the listing contains, live buying and delivery questions, research context, handling, testing and comparisons. Start with the quick answers, then open the topic group that matches your search.
Buying, price and availability
Australian Research Peptides supplies CJC-1295 (no DAC) + Ipamorelin within Australia. Orders can be paid by PayID or bank transfer. Anything confirmed before 12pm Sydney time, Monday to Friday, is dispatched that afternoon. The vial holds the no-DAC form rather than the DAC-modified peptide of nearly the same name, under code CJCIPA.
Delivery of CJC-1295 (no DAC) + Ipamorelin runs 2–5 business days by standard tracked post and 1–2 by Express Post to much of the country, with weekends and public holidays the thing that moves that date. Australian Research Peptides packs on business days only, so an order confirmed on a Saturday goes out Monday. Carriers may still move a parcel already lodged across a weekend.
Non-instant bank transfers batch on business days, which is why the window on a CJC-1295 (no DAC) + Ipamorelin order is counted in business days and pauses over weekends. A Friday-evening transfer that lands Monday is not late. Without that rule, a weekend order could expire before any bank had a chance to move the money.
Australian Research Peptides supplies CJC-1295 (no DAC) + Ipamorelin for in vitro research purposes only, and never as a medicine. ARP makes no claim that it is registered or approved for use in people or animals. Anyone unsure where their intended work sits should take their own regulatory advice.
Identity, names and exact format
CJC-1295 (no DAC) + Ipamorelin is a two-peptide blend in one vial: one peptide that binds the growth-hormone-releasing hormone receptor, paired with one that binds the growth hormone secretagogue receptor. Two different receptor targets is the reason the pair is studied together. The no DAC part matters — this is the unmodified form, not the DAC-modified version, which carries an extra lysine that sticks to albumin, a blood protein.
A CJC-1295 (no DAC) + Ipamorelin vial usually clears within a few minutes once the diluent has been run down the inside of the glass and the vial swirled. Freeze-dried peptide can take longer, occasionally up to an hour, and the two chains do not go into solution at identical speeds. Never shake it.
No — a sealed vial of this blend is dry lyophilised powder and travels and sits at ambient temperature without harm, which is why it posts with no cold pack. The fridge becomes necessary once water goes in. Dry and reconstituted are two different products as far as storage is concerned, with very different lifespans.
One — both peptides are freeze-dried together into a single powder inside one sealed, tamper-evident glass vial. This is not two vials boxed as a pair, and the two cannot be separated once dried. Anyone needing them apart can use Australian Research Peptides' standalone ipamorelin listing, which supplies that compound on its own.
The difference is receptor coverage. Ipamorelin alone is a single ligand at the growth hormone secretagogue receptor; the blend adds CJC-1295 (no DAC), a 29-residue GHRH-receptor analogue, so one vial carries two different receptor targets. Australian Research Peptides lists standalone ipamorelin as well, under GHRH and Secretagogue Research, if only the secretagogue is wanted.
Both are GHRH-receptor analogues and the structures differ: tesamorelin is GHRH(1-44) carrying a trans-3-hexenoyl group on its N-terminus, while the CJC-1295 (no DAC) half of this blend is a tetra-substituted GHRH(1-29). The blend then adds ipamorelin, a ligand at a second receptor that tesamorelin has no counterpart for. Australian Research Peptides lists both under GHRH and Secretagogue Research.
Research context and evidence
CJC-1295 (no DAC) + Ipamorelin pairs two peptides with two different receptor targets. The CJC-1295 half is 29 amino acids long, a modified copy of growth-hormone-releasing hormone, and binds the GHRH receptor, which sits on the growth-hormone cells of the pituitary gland at the base of the brain. Ipamorelin is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2 and binds the growth hormone secretagogue receptor instead, the one ghrelin binds. Both of those are laboratory binding measurements, not outcomes.
CJC-1295 (no DAC) and ipamorelin are paired in one vial because each binds its own receptor, so the two do not compete for one site. The CJC-1295 half binds the growth-hormone-releasing hormone receptor; ipamorelin binds the growth hormone secretagogue receptor, which ghrelin also binds. No published study has tested this exact pairing; each peptide has been studied separately in laboratory and animal models. Australian Research Peptides supplies the pair for in vitro research purposes only.
CJC-1295 (no DAC) + Ipamorelin sits in growth hormone research, where each half is known by the receptor it binds rather than by any outcome. CJC-1295 without DAC is a 29-amino-acid version of growth-hormone-releasing hormone with four positions changed; ipamorelin is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, which binds the growth hormone secretagogue receptor. Australian Research Peptides supplies the pair for in vitro research purposes only.
CJC-1295 (no DAC) + Ipamorelin holds two chains of very different length. The CJC-1295 half runs 29 amino acids, matching the first 29 of growth-hormone-releasing hormone with four positions swapped. Ipamorelin runs five, and two of its five are mirror-image D-forms that a plain sequence readout cannot tell from ordinary ones. Both chains dry into one powder rather than staying separate.
No. Neither peptide in this vial holds approval from any medicines regulator, and Australian Research Peptides supplies it for in vitro research purposes only. Nothing on this website is medical, therapeutic or usage advice. What ARP does publish about the material is chemical: the measured amount of each peptide, a result showing the DAC-modified form was not detected, and the certificate for the batch.
A CJC-1295 (no DAC) + Ipamorelin vial from Australian Research Peptides holds 10 mg in total, blended at the standard 1:1 ratio, so it is about 5 mg of each peptide. The two dry into one cake, which is why the strength on the label is the total for the pair rather than the amount of either one. Those are nominal formulation figures. Blend labels are genuinely ambiguous across the industry, because the same number can mean a combined total or that amount of each peptide. When an exact-strength batch document is published, its laboratory-measured amount for each chain takes precedence over the nominal formulation figures.
CJC-1295 (no DAC) and ipamorelin cannot be bought separately from Australian Research Peptides, because CJC-1295 has no standalone listing in the catalogue. Ipamorelin does. Drying the pair together fixes the ratio between them, which two vials filled from different batches cannot. The two bind different receptors, so the pairing is not two compounds at one target.
Handling, storage and measurements
Nothing has gone missing: both chains dry together as one deposit totalling ten milligrams, and spread across the floor of a glass container that amounts to a faint whitish bloom. Ipamorelin runs to five amino acids and its CJC-1295 partner to twenty-nine, yet neither contributes visible volume at these weights. A sealed, tamper-evident closure is better evidence of what is inside than anything the eye picks up.
Reconstituting CJC-1295 (no DAC) + Ipamorelin takes one preparation, because both peptides in the vial go into the same liquid. Add the diluent slowly, letting it run down the inside wall of the glass rather than landing on the powder. Swirl gently until the solid clears. Never shake. Keep the finished solution cold.
A reconstituted CJC-1295 (no DAC) + Ipamorelin vial goes to 2–8 °C and is allowed 8 to 12 weeks there by Australian Research Peptides' stated condition. Its CJC-1295 chain swaps four positions against growth-hormone-releasing hormone, and one swap exchanged the asparagine at position 8 for a glutamine — Bachem's shelf-life list names both, so that trade removed nothing.
The vial holds 10 mg in total across both peptides, and the ratio between them stays exactly as it was blended whatever volume is added. What the diluent cannot do is separate the two compounds — that is decided in the vial, not at the bench. Australian Research Peptides publishes no fill volume for this listing.
CJC-1295 (no DAC) + Ipamorelin holds two peptides that take up water at their own speeds, and the interval while the slower of them is still clearing can look like a fault. Microbubbles from swirling make it more pronounced. Several minutes at room temperature resolves both. What is genuinely abnormal is a preparation staying translucent rather than turning clear, or one throwing particles once left alone.
CJC-1295 (no DAC) + Ipamorelin arrives dry and is taken into solution with an aqueous diluent chosen for the method. A diluent is whatever liquid dissolves a freeze-dried powder, and one volume of it serves both peptides in the vial. Nothing liquid is packed with it, and the volume added sets the concentration.
Australian Research Peptides Pty Ltd is the company behind CJC-1295 (no DAC) + Ipamorelin, trading as ARP and posting to every state and territory, Western Australia and the Northern Territory included, by Express or tracked services. The blend sits in GHRH and Secretagogue Research beside tesamorelin and standalone ipamorelin, and is the only two-peptide entry of the three.
One price covers CJC-1295 (no DAC) + Ipamorelin, because Australian Research Peptides carries the blend at one strength only rather than a ladder of sizes. Each vial is quoted in Australian dollars, the figure taken live from its catalogue record. A vial of it and a vial of standalone ipamorelin count as separate lines on the order.
A pair of these blend vials clears the Standard tracked post threshold comfortably, while a single vial falls well short of free post. The Express Post waiver is a separate and higher bar that two vials do not reach. What the threshold reads is your goods subtotal before any discount code — qualification first, code afterwards, so one never cancels the other.
CJC-1295 (no DAC) + Ipamorelin is sold by Australian Research Peptides through its online catalogue alone, with no orders taken by telephone and none by email. Two routes are open, PayID or a straight bank transfer, while digital wallets, instalment accounts and crypto are not accepted for anything in the range. Stock is held and posted within Australia. When the blend is unavailable, an email alert can be registered against it.
Testing and batch documents
CJC 1295 is not sold on its own in Australia by Australian Research Peptides, which lists it to laboratories and researchers only as the two-peptide vial paired with ipamorelin, freeze-dried together as one catalogue line. A bare CJC-1295 listing usually means the DAC-modified analogue, a structurally different molecule carrying an extra lysine that binds albumin; the vial on this page is the no-DAC form, also catalogued as Modified GRF (1-29). Ipamorelin is listed separately if only that half is wanted, and nothing can pull the two chains apart once they are dried into one cake.
CJC1295 ipamorelin, cjc 1295 and ipamorelin, and cjc ipamorelin are typed forms of one listing: the single Australian Research Peptides vial holding both peptides freeze-dried together. The hyphen and the space are typography, not chemistry — CJC-1295 with a hyphen, CJC 1295 with a space and CJC1295 closed up name the same 29-residue chain. CPC 1295 turns up too, a keyboard slip for CJC rather than a second compound.
Ordering, payment and Australian delivery
A CJC-1295 (no DAC) + Ipamorelin vial is normally dissolved once, as a whole, because both peptides were dried together and cannot be separated at the bench. Splitting the finished solution into smaller portions on the day it is made avoids going back to the same vial again and again. The ratio between the two peptides stays as blended.
No authority has licensed either component of the CJC-1295 (no DAC) + Ipamorelin blend, so the pairing has no American approval and none elsewhere. Neither compound ever reached a marketed product. Tesamorelin is the rare growth-hormone-axis peptide that did win approval; neither of these two did. Both are supplied as unregistered research material with no label behind them.
CJC-1295 (no DAC) + Ipamorelin is on the World Anti-Doping Agency's prohibited list: CJC-1295 is named among the GHRH analogues in section S2.2, and ipamorelin among the growth hormone secretagogues in that same section. Both peptides are prohibited in and out of competition. Anti-doping enforcement in Australia rests with Sport Integrity Australia.
Neither peptide in this blend is registered as a medicine anywhere in the world, so there is no approved foreign product to bring in under a personal-importation exemption — the scheme assumes something a regulator somewhere has licensed. The TGA controls what unapproved goods may enter and Border Force applies that at the frontier. Australian Research Peptides posts this blend from Australian stock, so an order is not an import and waits on no clearance — the reason domestic supply reaches a bench faster than an overseas consignment. What that removes is a customs step, not the buyer's own responsibility for what they hold.
Access and regulatory questions
Yes. CJC-1295 (no DAC) + Ipamorelin is tested ahead of supply, and the report states each peptide's measured content separately: Ipamorelin and CJC-1295 (mod GRF 1-29) in milligrams, with CJC-1295 DAC recorded as not detected. The manufacturer commissions an independent laboratory to run the analyses for Australian Research Peptides. Mass spectrometry checks the measured mass against two expected values, one for each peptide, which is what separates the no-DAC compound from the DAC-modified one sharing most of the name. CJC-1295 (no DAC) + Ipamorelin is supplied for in vitro research purposes only.
The certificate for the batch that vial came from, not a general document for the listing. Australian Research Peptides publishes the certificates it holds in its COA library, searchable by product name and stock code. Send us your order reference and we will match the certificate to what you were sent.
CJC-1295 (no DAC) + Ipamorelin has no single scientific synonym because it contains two peptides. CJC-1295 without DAC is also catalogued as Modified GRF (1-29), often shortened to Mod GRF 1-29, while Ipamorelin carries the development code NNC 26-0161. Australian Research Peptides uses CJCIPA as the catalogue code for this specific two-peptide vial.
Australian Research Peptides supplies this CJC-1295 listing in the no-DAC form, also catalogued as Modified GRF (1-29). The DAC version carries an extra lysine bearing a Drug Affinity Complex, which binds serum albumin, a protein carried in the bloodstream. That makes it a structurally different molecule, and it is not listed here. Contact Australian Research Peptides support if the DAC form is what the work needs.